Extended Data Fig. 4: Dual spleen and symptom responses.
From: Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial
SVR35, ≥35% reduction in spleen volume; TSS50, ≥50% reduction in total symptom score.
Extended Data Fig. 4: Dual spleen and symptom responses. | Nature Medicine
